Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Percheron Therapeutics ( (AU:PER) ) has provided an announcement.
Percheron Therapeutics has announced that the phase IIb study of avicursen for Duchenne muscular dystrophy did not show efficacy, leading to the study’s termination and a strategic review of the company’s pipeline. Despite the setback, the company completed a $13.0 million institutional placement and a $1.85 million Share Purchase Plan, with funds redirected to pursue new opportunities that could enhance shareholder value.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for rare diseases.
YTD Price Performance: -5.00%
Average Trading Volume: 4,916
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $6.78M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.
